Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma

Abstract

To investigate the efficacy and safety of the FEAC (fotemustine, etoposide, cytarabine, and cyclophosphamide) conditioning regimen for the treatment of lymphoma, we retrospectively analyzed the records of 76 Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients who underwent autologous stem cell transplantation (ASCT) after the FEAC conditioning regimen. Their survival, as well as the clinical efficacy, hematopoietic engraftment time, and toxicity, were analyzed. One patient died of severe pulmonary infection, and the transplant-related mortality (TRM) was 1.3% (1/76). Hematopoietic engraftment was achieved successfully in the remaining 75 patients. The median times of neutrophil and platelet engraftment were 11 d (6–21 d) and 13 d (8–24 d), respectively. The 2-year progression-free survival (PFS) rate was 69.1%, and the 2-year overall survival (OS) rate was 84.2%. FEAC conditioning regimen has acceptable toxicity, and the prognosis of patients is good, making it a feasible alternative to the BEAM regimen for ASCT.

Keywords:

• FEAC
• fotemustine
• cyclophosphamide
• autologous stem cell transplantation
• lymphoma

Acknowledgments

This work was supported by the department of oncology, the First Affiliated Hospital of Zhengzhou University.

Author contributions

ML and XW collected and analyzed the clinical data, performed the statistical analysis, and wrote the manuscript. All the authors performed clinical research and provided data. All the authors reviewed, analyzed, and finalized the manuscript.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

There is no funding associated with the work featured in this article.